# Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

Study · id `cardio:ct-nct06047262` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06047262](<https://clinicaltrials.gov/study/NCT06047262>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06047262

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06047262. Randomized; double masking; primary purpose treatment. Start 2024-07-09 (actual); primary completion 2028-07-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06047262, source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)
- Started: 2024-07-09 (actual) (ClinicalTrials.gov record NCT06047262, source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)
- Primary completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT06047262, source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)
- Completion: 2028-07-31 (anticipated) (ClinicalTrials.gov record NCT06047262, source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)
- Countries: Belgium; France; Germany; Switzerland (ClinicalTrials.gov record NCT06047262, source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06047262-2026-02-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia
- Acronym: Dapan-Dia
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Dapansutrile
- Intervention (Drug): Placebo
- Lead sponsor: Marc Donath
- Lead sponsor class: OTHER
- Collaborator: European Union
- Collaborator class: OTHER
- Collaborator: State Secretariat for Education Research and Innovation, Switzerland
- Collaborator class: OTHER
- Collaborator: Olatec Therapeutics, Inc.
- Collaborator class: INDUSTRY
- Collaborator: Departement Klinische Forschung Universität Basel
- Collaborator class: UNKNOWN
- Collaborator: CTU Kantonsspital Baden
- Collaborator class: UNKNOWN

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as a collaborator: European Union (`cardio:org-european-union`)

## Provenance

Content hash: b32a3046cb5c6ddcd60c185364708ac77da16fb51bf4cd2b75be5f521550134f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
